公开(公告)号：US20240287025A1

公开(公告)日：2024-08-29

申请号：US18563306

申请日：2022-05-24

申请人： Centre National de la Recherche Scientifique ,  Commissariat à l'Energie Atomique et aux Energies Alternatives ,  Centre Hospitalier Universitaire de Grenoble Alpes ,  Institut National de la Santé et de la Recherche Médicale ,  UNIVERSITE GRENOBLE ALPES

发明人： Zuzana MACEK JILKOVA ,  Jérôme GOVIN ,  Anouk EMADALI ,  Carlo PETOSA ,  Yung-Sing WONG

IPC分类号： C07D401/12 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/695 ,  A61P29/00 ,  C07D215/42 ,  C07D215/48 ,  C07D401/04 ,  C07D401/14 ,  C07F7/18 ,  C07F11/00

CPC分类号： C07D401/12 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/695 ,  A61P29/00 ,  C07D215/42 ,  C07D215/48 ,  C07D401/04 ,  C07D401/14 ,  C07F7/1804 ,  C07F11/00

摘要： The present invention relates to new tetrahydroquinoline (THQ) compounds and new methods for synthetizing such compounds.
The present invention relates to the applications thereof, in particular in therapeutic treatment.
The present invention relates in particular to compound having the following structure:




wherein R, R′, RA, Nu, R1, R2, R3, and R4 are each independently an atom or a chemical group of atoms.

公开(公告)号：US20240277694A1

公开(公告)日：2024-08-22

申请号：US18588191

申请日：2024-02-27

申请人： Neurodon Corporation

发明人： Russell Dahl

IPC分类号： A61K31/4706 ,  A61K31/4709 ,  A61P3/10

CPC分类号： A61K31/4706 ,  A61K31/4709 ,  A61P3/10

摘要： Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

公开(公告)号：US12036218B2

公开(公告)日：2024-07-16

申请号：US17465087

申请日：2021-09-02

申请人： Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.

发明人： Antje Prasse ,  Jonas Schupp

IPC分类号： A61K31/4706 ,  A61P11/00 ,  G01N33/68

CPC分类号： A61K31/4706 ,  A61P11/00 ,  G01N33/6893 ,  G01N2800/12

摘要： The invention is based on the finding that Airway Basal Cells (ABCs) play a key role in the pathobiology of various lung diseases. The invention therefore provides approaches for the treatment and prevention of lung diseases such as fibrotic disorders, pre stages of fibrosis, Chronic Obstructive Lung Diseases (COPD) or other lung disorders. Diseases treatable with the means and methods of the invention are characterized by a cellular remodelling in the alveolar compartment of the lung. Furthermore, the invention provides screening approaches to identify compounds suitable for the treatment of lung diseases.

公开(公告)号：US20240199620A1

公开(公告)日：2024-06-20

申请号：US18389182

申请日：2023-11-13

申请人： RAPT THERAPEUTICS, INC.

发明人： Hilary Plake Beck ,  Berenger Biannic ,  Minna Hue Thanh Bui ,  Dennis X. Hu ,  John Michael Ketcham ,  Jay Patrick Powers ,  Maureen Kay Reilly ,  Omar Robles-Resendiz ,  Hunter Paul Shunatona ,  James Ross Walker ,  David Juergen Wustrow ,  Ashkaan Younai ,  Mikhail Zibinsky ,  Jeffrey J. Jackson

IPC分类号： C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

CPC分类号： C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

摘要： Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

公开(公告)号：US11944632B2

公开(公告)日：2024-04-02

申请号：US17520787

申请日：2021-11-08

申请人： SAVA HEALTHCARE LTD

发明人： Sriram Padmanabhan ,  Vinod Ramchandra Jadhav

IPC分类号： A61K31/53 ,  A61K9/00 ,  A61K9/16 ,  A61K31/4045 ,  A61K31/4706 ,  A61K31/4965 ,  A61K31/675 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  A61K39/395 ,  A61P31/14

CPC分类号： A61K31/53 ,  A61K9/0075 ,  A61K9/1623 ,  A61K31/4045 ,  A61K31/4706 ,  A61K31/4965 ,  A61K31/675 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  A61K39/3955 ,  A61P31/14

摘要： The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:




for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

公开(公告)号：US11903936B2

公开(公告)日：2024-02-20

申请号：US17787378

申请日：2020-12-18

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  MMV MEDICINES FOR MALARIA VENTURE

发明人： Margaret Phillips ,  Michael Palmer ,  Susan A. Charman ,  Karl Shawn Watts ,  Aleksey I. Gerasyuto ,  Goran Krilov

IPC分类号： C07D401/14 ,  A61P33/06 ,  A61K31/4439 ,  A61K31/122 ,  A61K31/137 ,  A61K31/155 ,  A61K31/366 ,  A61K31/4196 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/65 ,  C07D403/12

CPC分类号： A61K31/4439 ,  A61K31/122 ,  A61K31/137 ,  A61K31/155 ,  A61K31/366 ,  A61K31/4196 ,  A61K31/473 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/65 ,  A61P33/06 ,  C07D401/14 ,  C07D403/12

摘要： The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

公开(公告)号：US20240016793A1

公开(公告)日：2024-01-18

申请号：US18229474

申请日：2023-08-02

申请人： Neurodon Corporation

发明人： Russell Dahl

IPC分类号： A61K31/4706 ,  A61P3/10 ,  A61K31/4709

CPC分类号： A61K31/4706 ,  A61P3/10 ,  A61K31/4709

摘要： Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

公开(公告)号：US11833122B2

公开(公告)日：2023-12-05

申请号：US15776698

申请日：2016-11-17

申请人： Calgent Biotechnology Co., Ltd.

发明人： Yun Yen ,  Jing-ping Liou ,  Chien Huang Lin

IPC分类号： A61P1/16 ,  A61K31/4706 ,  A61K31/166 ,  A61K45/06 ,  A61K9/20 ,  A61K9/48 ,  A61K31/426 ,  A61K31/4409 ,  C07C15/00 ,  A61P11/00 ,  A61K31/40 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5375 ,  A61K9/00

CPC分类号： A61K31/166 ,  A61K9/20 ,  A61K9/48 ,  A61K31/40 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5375 ,  A61K45/06 ,  A61P11/00 ,  C07C15/00 ,  A61K9/0019 ,  A61K31/40 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/415 ,  A61K2300/00 ,  A61K31/4184 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/44 ,  A61K2300/00 ,  A61K31/4402 ,  A61K2300/00 ,  A61K31/4406 ,  A61K2300/00 ,  A61K31/4453 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00 ,  A61K31/4706 ,  A61K2300/00 ,  A61K31/495 ,  A61K2300/00 ,  A61K31/4965 ,  A61K2300/00 ,  A61K31/505 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/5375 ,  A61K2300/00 ,  A61K31/4409 ,  A61K2300/00 ,  A61K31/426 ,  A61K2300/00

摘要： The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

公开(公告)号：US20230338285A1

公开(公告)日：2023-10-26

申请号：US18044217

申请日：2021-09-13

申请人： Philip Morris Products S.A.

发明人： Florian Alexis CALVINO ,  Philippe Alexandre GUY ,  Julia HOENG ,  Aditya Reddy KOLLI ,  Arkadiusz KUCZAJ ,  Shoaib MAJEED ,  Anatoly MAZUROV ,  Manuel PEITSCH ,  Tanja Zivkovic SEMREN ,  Marco VAN DER TOORN

IPC分类号： A61K9/00 ,  A61K31/4706 ,  A61K47/10

CPC分类号： A61K9/0078 ,  A61K31/4706 ,  A61K47/10

摘要： A pharmaceutical composition may include hydroxychloroquine or a pharmaceutically acceptable salt thereof, and a solvent. The pharmaceutical composition may include 1 to 400 mg/mL hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1,3-diol and water or combinations thereof and. The pharmaceutical composition may be suitable for thermal aerosolization. A pharmaceutical composition including hydroxychloroquine or a pharmaceutically acceptable salt thereof may be used in the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is administered by oral inhalation.

公开(公告)号：US20230270715A1

公开(公告)日：2023-08-31

申请号：US17824621

申请日：2022-05-25

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Dong H. Kim ,  Yanning Rui ,  Zhen Xu ,  John Hagan

IPC分类号： A61K31/37 ,  A61K31/4706 ,  A61K31/55 ,  A61K31/52 ,  A61K31/351 ,  A61K38/10 ,  A61P9/10

CPC分类号： A61K31/37 ,  A61K31/52 ,  A61K31/55 ,  A61K31/351 ,  A61K31/4706 ,  A61K38/10 ,  A61P9/10

摘要： Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.